Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG vaccine plus single-dose rifampicin for household contacts under 15 years old of patients with leprosy
RBR-6yg2z9Not yet recruiting
- Sponsor
- Universidade Federal de Mato Grosso
- Start
- Aug 2019
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of bcg vaccine and rifampicin in leprosy (HD), sponsored by Universidade Federal de Mato Grosso. Primary endpoint: Not reported. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
bcg vaccinerifampicin
03
Conditions
leprosy (HD)
Beyond the preview
Go deeper on RBR-6yg2z9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-6yg2z9.